Get the Stockscreener App
13.06
3.86%
0.485
Pre-market:
13.23
0.165
+1.26%
Benitec Biopharma Inc stock is traded at $13.06, with a volume of 443.44K.
It is up +3.86% in the last 24 hours and down -16.84% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$12.58
Open:
$12.49
24h Volume:
443.44K
Relative Volume:
2.81
Market Cap:
$442.41M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.193
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
+0.38%
1M Performance:
-16.84%
6M Performance:
-15.63%
1Y Performance:
+32.64%
1-Day Range:
$12.49
$13.20
1-Week Range:
$11.54
$13.20
52-Week Range:
$9.49
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
13.06 | 425.99M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) - Yahoo Finance
Benitec Biopharma shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
Benitec Biopharma shareholders approve all proposals at annual meeting - Investing.com
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting - TipRanks
Price-Driven Insight from (BNTC) for Rule-Based Strategy - news.stocktradersdaily.com
Can Benitec Biopharma Inc. stock continue upward trendJuly 2025 Momentum & AI Enhanced Execution Alerts - Newser
Risk Check: Can Benitec Biopharma Inc. stock double in next 5 years - BỘ NỘI VỤ
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others - AOL.com
Why Benitec Biopharma Inc. stock could be next big winner2025 Key Lessons & Weekly Momentum Picks - moha.gov.vn
Can Benitec Biopharma Inc. stock double in next 5 yearsJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - moha.gov.vn
HC Wainwright Has Optimistic Outlook of BNTC FY2026 Earnings - MarketBeat
Q2 Earnings Estimate for BNTC Issued By HC Wainwright - Defense World
BNTC Analyst Rating Maintained but Price Target Lowered to $32 b - GuruFocus
HC Wainwright & Co. Maintains Benitec Biopharma (BNTC) Buy Recommendation - MSN
Benitec Biopharma (NASDAQ:BNTC) Rating Increased to Hold at Wall Street Zen - Defense World
Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy - MSN
(BNTC) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Is Benitec Biopharma Inc. stock a smart buy before Fed meetingWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
[Form 4] Benitec Biopharma Inc. Insider Trading Activity - Stock Titan
Pattern recognition hints at Benitec Biopharma Inc. upsideJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Can Benitec Biopharma Inc. stock sustain market leadershipEarnings Miss & Risk Managed Trade Strategies - newser.com
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Benitec Biopharma Inc. a candidate for recovery play2025 Top Gainers & Trade Opportunity Analysis - newser.com
Is Benitec Biopharma Inc. stock affected by interest rate hikesLong Setup & Reliable Intraday Trade Alerts - newser.com
Strategies to average down on Benitec Biopharma Inc.July 2025 Recap & Technical Buy Zone Confirmations - newser.com
Benitec Biopharma Inc. recovery potential after sell off2025 Buyback Activity & Risk Controlled Stock Alerts - newser.com
Is Benitec Biopharma Inc. stock attractive for growth ETFs2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Can a trend reversal in Benitec Biopharma Inc. lead to recoveryProfit Target & Community Consensus Trade Alerts - newser.com
Citizens reiterates Market Outperform rating on Benitec BioPharma stock By Investing.com - Investing.com Canada
Real time social sentiment graph for Benitec Biopharma Inc.2025 Market Overview & Fast Moving Market Watchlists - newser.com
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment - Finviz
Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses - MSN
Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership - Yahoo Finance
Citizens reiterates Market Outperform rating on Benitec BioPharma stock - Investing.com India
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid sector headwinds - Investing.com Nigeria
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid sector headwinds By Investing.com - Investing.com South Africa
Benitec Biopharma Completes $100 Million Equity Offerings - Global Legal Chronicle
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 31 '25 |
Buy |
12.83 |
16,497 |
211,736 |
8,807,805 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):